open access

Vol 58, No 2 (2007)
Original papers
Published online: 2007-03-13
Submitted: 2013-02-15
Get Citation

Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves’ ophthalmopathy

Janusz Myśliwiec, Małgorzata Adamczyk, Przemysław Pawłowski, Agnieszka Nikołajuk, Maria Górska
Endokrynologia Polska 2007;58(2):105-109.

open access

Vol 58, No 2 (2007)
Original papers
Published online: 2007-03-13
Submitted: 2013-02-15

Abstract

Introduction: The aim of this study was to estimate the influence of corticosteroids on soluble MMP-2, MMP-9 and VCAM-1 in patients with Graves’ ophthalmopathy (GO) in order to assess their usefulness as a guideline in a therapeutic approach.
Material and methods: Serum gelatinases and VCAM-1 were detected in three groups of subjects: 20 patients with GO (CAS ≥ 3, anamnesis of GO ≥ 1 yr), 12 patients with no clinical symptoms of ophthalmopathy (Gd) and 10 healthy volunteers. Corticosteroid therapy consisted of intravenous infusions (2 series, 3 grams each time) of methylprednisolone (MP) and subsequent treatment with oral prednisone (60 mg per day) in a tapering schedule. The serum samples were collected 24 hours before MP, 24 hours after MP, after 14 days of treatment with prednisone and at the end of corticosteroid therapy. The levels of soluble MMP-2, MMP-9 and VCAM-1 were determined by the ELISA method.
Results: We have found no differences in serum MMP-2 between the groups studied and a significant reduction after MP only in corticosteroid-resistant GO patients. Soluble MMP-9 was highest in the GO group compared with both the Gd and control individuals. Moreover serum MMP-9 decreased in corticosteroid-responsive GO patients after MP and remained at the lower level at the end of the study. Positive correlations between MMP-2 and MMP-9 before and after MP administration were observed. Serum VCAM-1 was significantly elevated both in GO and Gd subjects and pre-treatment VCAM-1 levels were elevated in corticosteroid-responders compared with non-responders.
Conclusions: Our results suggest that serum VCAM-1 may serve as a marker predicting the efficacy of corticosteroids and that soluble MMP-9 may be helpful in monitoring corticosteroid administration and in decision-making with regard to further GO treatment.

Abstract

Introduction: The aim of this study was to estimate the influence of corticosteroids on soluble MMP-2, MMP-9 and VCAM-1 in patients with Graves’ ophthalmopathy (GO) in order to assess their usefulness as a guideline in a therapeutic approach.
Material and methods: Serum gelatinases and VCAM-1 were detected in three groups of subjects: 20 patients with GO (CAS ≥ 3, anamnesis of GO ≥ 1 yr), 12 patients with no clinical symptoms of ophthalmopathy (Gd) and 10 healthy volunteers. Corticosteroid therapy consisted of intravenous infusions (2 series, 3 grams each time) of methylprednisolone (MP) and subsequent treatment with oral prednisone (60 mg per day) in a tapering schedule. The serum samples were collected 24 hours before MP, 24 hours after MP, after 14 days of treatment with prednisone and at the end of corticosteroid therapy. The levels of soluble MMP-2, MMP-9 and VCAM-1 were determined by the ELISA method.
Results: We have found no differences in serum MMP-2 between the groups studied and a significant reduction after MP only in corticosteroid-resistant GO patients. Soluble MMP-9 was highest in the GO group compared with both the Gd and control individuals. Moreover serum MMP-9 decreased in corticosteroid-responsive GO patients after MP and remained at the lower level at the end of the study. Positive correlations between MMP-2 and MMP-9 before and after MP administration were observed. Serum VCAM-1 was significantly elevated both in GO and Gd subjects and pre-treatment VCAM-1 levels were elevated in corticosteroid-responders compared with non-responders.
Conclusions: Our results suggest that serum VCAM-1 may serve as a marker predicting the efficacy of corticosteroids and that soluble MMP-9 may be helpful in monitoring corticosteroid administration and in decision-making with regard to further GO treatment.
Get Citation

Keywords

Graves' ophthalmopathy; gelatinases; VCAM-1; corticosteroids

About this article
Title

Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves’ ophthalmopathy

Journal

Endokrynologia Polska

Issue

Vol 58, No 2 (2007)

Pages

105-109

Published online

2007-03-13

Bibliographic record

Endokrynologia Polska 2007;58(2):105-109.

Keywords

Graves' ophthalmopathy
gelatinases
VCAM-1
corticosteroids

Authors

Janusz Myśliwiec
Małgorzata Adamczyk
Przemysław Pawłowski
Agnieszka Nikołajuk
Maria Górska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl